Overview
Rybrevant Faspro is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic (advanced) non-small cell lung cancer (NSCLC) that has specific…
Overview
Rybrevant is approved by the U.S. Food and Drug Administration (FDA) for the treatment of lung cancer. It is specifically indicated for adults with locally advanced or metastatic non-small cell lung cancer…